The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

To maintain vaccine efficacy, WHO regularly updates influenza vaccine strains based on global epidemiological, virological, ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Catani and colleagues provide data on antigenic properties of neuraminidase proteins of pandemic H1N1 and show that antigenic diversity of the neuraminidase from 2009 to 2020 largely falls into two ...

Researchers have taken a major step towards producing a more affordable and lower-risk polio vaccine using virus-like ...

CLEVELAND, Ohio — Eggs are disappearing from store shelves due to shortages caused by the avian flu outbreak, but never fear ...

The Phase 1 trial is an open label, dose ranging clinical study designed to evaluate Vaxart’s second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs.

Multiple sclerosis (MS) and other conditions affecting the immune system can activate the John Cunningham (JC) virus, causing a potentially life threatening infection. The JC virus is common ...

In the outbreak of Ebola virus disease (EVD) in the Democratic Republic of Congo (DRC) between 2018 and 2020, ring ...

GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults: London, UK Saturday, March 8, 2025, 14:00 Hrs [IST] GSK plc will share its ...